 Immunotherapy
"Immunotherapy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection.
| Descriptor ID |
D007167
|
| MeSH Number(s) |
E02.095.465.425
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Immunotherapy".
Below are MeSH descriptors whose meaning is more specific than "Immunotherapy".
This graph shows the total number of publications written about "Immunotherapy" by people in this website by year, and whether "Immunotherapy" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 2 | 0 | 2 | | 1997 | 2 | 2 | 4 | | 1998 | 0 | 1 | 1 | | 1999 | 2 | 3 | 5 | | 2000 | 1 | 0 | 1 | | 2002 | 2 | 3 | 5 | | 2003 | 4 | 3 | 7 | | 2004 | 1 | 2 | 3 | | 2005 | 1 | 2 | 3 | | 2006 | 7 | 5 | 12 | | 2007 | 1 | 4 | 5 | | 2008 | 11 | 1 | 12 | | 2009 | 5 | 3 | 8 | | 2010 | 5 | 6 | 11 | | 2011 | 4 | 5 | 9 | | 2012 | 7 | 2 | 9 | | 2013 | 9 | 5 | 14 | | 2014 | 11 | 4 | 15 | | 2015 | 13 | 10 | 23 | | 2016 | 11 | 9 | 20 | | 2017 | 16 | 9 | 25 | | 2018 | 14 | 17 | 31 | | 2019 | 24 | 13 | 37 | | 2020 | 23 | 22 | 45 | | 2021 | 25 | 25 | 50 | | 2022 | 6 | 27 | 33 | | 2023 | 3 | 27 | 30 | | 2024 | 12 | 17 | 29 | | 2025 | 17 | 13 | 30 | | 2026 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Immunotherapy" by people in Profiles.
-
He K, Forde PM, Govindan R, Santoro A, Gettinger S, Borghaei H, Spira A, Chu Q, Zinner R, Schoenfeld AJ, Camidge DR, Spigel DR, Gurpide A, Juergens RA, Laurie SA, Cerra M, Spires T, Greenawalt DM, Rapoport I, Gainor JF. Fast Real-Time Assessment of Combination Therapies in Immuno-ONcology in patients with advanced non-small-cell lung cancer (FRACTION-Lung). ESMO Open. 2026 Mar; 11(3):106078.
-
Prawira A, Xu H, Mei Y, Leow WQ, Nasir NJM, Reolo MJ, Otsuka M, Rahbari M, Chen Z, Weerasooriya M, Abdullah LB, Wu J, Hazirah SN, Wasser M, Chung A, Goh BK, Chow PK, Albani S, Lee J, Lim TKH, Zhai W, Dan YY, Goh GB, Heikenwälder MF, Zhang Y, Dasgupta R, Tai WMD, Liu H, Chen J, Chew V. Targeting Treg-fibroblast interaction to enhance immunotherapy in steatotic liver disease-related hepatocellular carcinoma. Gut. 2025 Dec 05; 75(1):105-118.
-
Kuo C, Giannikou K, Wang N, Warren M, Goodspeed A, Shillingford N, Hayashi M, Raredon MSB, Amatruda JF. Spatial Profiling Identifies Tumor-Associated Stroma Enrichment and MIF as Potential Immunotherapy Targets in Primary Ewing Sarcomas. Clin Cancer Res. 2025 Dec 01; 31(23):5051-5069.
-
Fujiwara Y, Komohara Y. Therapeutic Strategies Targeting CD163 and CD169 in Macrophages for Cancer. Pathol Int. 2025 Nov; 75(11):551-561.
-
Molina-Cerrillo J, Roviello G, Bourlon MT, Studentova H, Fiala O, Cerbone L, Kucharz J, Ansari J, Zeppellini A, Taha T, Buti S, Ürün Y, Scagliarini S, Li H, Sunela K, Park SH, Rizzo M, Zgura A, Chiari R, Seront E, Catalano M, Ghosn M, Filosa A, Soares A, Massari F, Monteiro FSM, Grande E, Porta C, Bracarda S, Santoni M. Toxicity-related immunotherapy discontinuation and outcome in patients with advanced renal cell carcinoma treated with immune-based combinations (ARON-1 study). Int J Cancer. 2026 Mar 01; 158(5):1396-1405.
-
Wang J, Huang X, Shi Q, Swingle KL, Hamilton AG, Gong N, Mitchell MJ. Drug-loaded bispecific T cell nanoengager overcomes T cell exhaustion for potent cancer immunotherapy. Proc Natl Acad Sci U S A. 2025 Nov 11; 122(45):e2409564122.
-
Sharman JP, Egyed M, Jurczak W, Skarbnik A, Patel K, Flinn IW, Kamdar M, Munir T, Walewska R, Hughes M, Fogliatto LM, Herishanu Y, Banerji V, Follows G, Walker P, Ghia P, Janssens A, Byrd JC, Ferrant E, Ferrajoli A, Wierda WG, Wachira CW, Suterwala BT, Miranda P, Munugalavadla V, Wun CC, Woyach JA. Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN. Blood. 2025 Sep 11; 146(11):1276-1285.
-
Weis AM, Bauer KM, Tang WW, Stephen-Victor E, Bell R, Brown DG, Ekiz HA, Tran V, Klag KA, Swanson EA, Barrios L, Harwood M, Hill JH, Ost KS, Gigic B, Schneider M, Ose J, Hardikar S, Toriola AT, Shibata D, Li CI, Figueiredo JC, Byrd DA, Siegel EM, Arnolds K, Lozupone C, Ulrich CM, O'Connell RM, Stephens WZ, Round JL. A capsular polysaccharide from a healthy human microbiota member activates a Lag-3-NK cell axis to restrain colon cancer and augment immunotherapy. Cell Rep. 2025 Sep 23; 44(9):116172.
-
Guillemaud M, Hanin A, Riviello JJ, Chavez M, Batra A, Berry M, Bisulli F, Castillo-Pinto C, Cobos-Hernandez C, Demeret S, Eschbach K, Farias-Moeller R, Fields M, Gaspard N, Gerard EE, Gofton TE, Gopaul MT, Gruen MD, Jimenez AD, Kazazian K, Kim M, Mansour M, Marcuse L, Marois C, Morales M, Muccioli L, Pasini E, Pham MM, Rosas SP, Struck AF, Torcida N, Wainwright MS, Yoo JY, Muscal E, Navarro V, Hirsch LJ, Lai Y. Standard complete blood count to predict long-term outcomes in febrile infection-related epilepsy syndrome (FIRES): A multicenter study. Epilepsia. 2025 Dec; 66(12):4780-4794.
-
Narikawa Y, Kuramasu A, Hosonuma M, Murayama M, Funayama E, Sasaki A, Baba Y, Toyoda H, Isobe J, Tajima K, Nakashima R, Sasaki A, Maruyama Y, Yamazaki Y, Shida M, Tsurui T, Hirasawa Y, Ariizumi H, Ishiguro T, Suzuki R, Ohkuma R, Kubota Y, Sambe T, Tsuji M, Wada S, Horiike A, Kobayashi S, Tsunoda T, Kobayashi S, Kobayashi H, Oguchi T, Shimane T, Kiuchi Y, Yoshimura K. Inosine shapes PD-1 blockade responses and synergizes with dual PD-1/CTLA-4 immunotherapy to enhance antitumor immunity. Cancer Immunol Immunother. 2025 Aug 19; 74(9):289.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|